Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14595101 | 0.79 | GPR119 (0.33) | GPR119LMNAGAAMAPTL3MBTL1 | |
| SCHEMBL4945993 | 0.79 | PHGDH (0.43) | LMNAGAAMAPT | |
| SCHEMBL23752208 | 0.74 | NCF1 (0.43) | LMNA | |
| SCHEMBL4944085 | 0.74 | NAMPT (0.33) | — | |
| SCHEMBL4586883 | 0.74 | — | — | |
| SCHEMBL4313579 | 0.73 | GAA (0.47) | GAAMAPT | |
| SCHEMBL311407 | 0.72 | F2 (0.48) | LMNAMAPTHTT | |
| SCHEMBL4586891 | 0.71 | EPHX1 (0.39) | HTT | |
| SCHEMBL2527566 | 0.70 | F2 (0.52) | GPR119GAA | |
| SCHEMBL9059677 | 0.70 | F2 (0.52) | GPR119GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853213-B2 | Bicyclic compound for modulating G protein-coupled receptors | HANMI PHARM. CO., LTD (KR) | 2014-10-07 | — | — | US | disclosed |
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | HANMI PHARM. CO., LTD (KR) | 2013-10-17 | — | — | US | disclosed |
| EP-2013201-B1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-2013201-A1 | HETEROCYCLIC GPCR AGONISTS | Prosidion Limited (GB) | 2009-01-14 | — | — | EP | disclosed |
| WO-2007116229-A1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274268-A1 | NEW BICYCLIC COMPOUND FOR MODULATING G PROTEIN-COUPLED RECEPTORS | GPR119, GPR65, GPR3 | GPR119 1/4885LMNA 4228/4885GAA 3148/4885 |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GLP1R | GPR119 1/4885LMNA 4600/4885GAA 1873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.